Mylan (NASDAQ: MYL), a global pharmaceutical company, has voluntarily waived its exclusive rights to distribute its generic version of Kaletra (lopinavir/ritonavir) antiretroviral 100mg/25mg and 200mg/50mg tablets in the United States, it was reported on Wednesday.
This move is intended to help increase the available supply of the product should it prove effective in the treatment of coronavirus. It will allow the company to enable other generic applicants to be eligible for FDA approval of their medicines for patients in the United States, expanding access in the event that additional clinical studies or other evaluations conclude that the product may be effective in treating COVID-19.
The company was the first to file a substantially complete abbreviated new drug application with the Food and Drug Administration (FDA) to launch a generic version of this product to market, entitling the company to a 180-day marketing exclusivity period upon final FDA approval, which is pending.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML